More than 500 Biden Administration employees have reportedly signed an open letter urging the president to call for a ceasefire between Israel and Hamas. These employees may be using their roles in the federal government to undercut efforts aimed at supporting Israel....
U.S. Senator Marco Rubio’s (R-FL) office will host in-person Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of Senator Rubio’s...
El pasado domingo, el pueblo argentino eligió democráticamente a su futuro presidente. El senador estadounidense Marco Rubio (R-FL) emitió el siguiente comunicado tras la elección de Javier Milei. “Felicitaciones al pueblo de Argentina por una elección pacífica y...
This past Sunday, the people of Argentina democratically elected their future President. U.S. Senator Marco Rubio (R-FL) released a statement following the election of Javier Milei. “Congratulations to the people of Argentina on their peaceful and democratic...
Millions of Americans are feeling the effects of the bad economy as they head home for Thanksgiving. Virtually across the board, they are met with increased food, gas, and travel costs. U.S. Senator Marco Rubio (R-FL) released a video on the failure of President Joe...
Marco Rubio encabeza la lista de los legisladores más eficaces de Florida y ocupa el segundo lugar a nivel nacional 15 de noviembre del 2023 Informe Orwell Anualmente, el Centro para una Legislación Efectiva (CEL) de la Universidad de Virginia y la Universidad de...
Rubio, Warren Introduce Bill to Address U.S. Overreliance on Foreign Pharmaceuticals
Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Elizabeth Warren (D-MA) introduced the Strengthening Supply Chains for Servicemembers and Security Act to address the national security risk posed by the United States’ reliance on foreign entities for pharmaceuticals. The legislation follows a September 2021 report from the Department of Defense (DoD) Office of Inspector General (OIG) that confirmed the DoD is over-reliant on foreign made pharmaceuticals without sufficient strategies to address domestic supply chain dysfunction. The Senators successfully secured language in the National Defense Authorization Act for Fiscal Year 2021 to require an industrial capacity vulnerability study of the DoD’s dependence on foreign-made pharmaceuticals.
“The report from the Department of Defense Office of Inspector General only confirms what was made glaringly obvious during the COVID-19 pandemic: the United States remains dangerously reliant on foreign nations for its pharmaceuticals,” Rubio said. “It is unacceptable that we do not currently have a plan in place to address these supply chain issues. I’m proud to introduce this legislation to ensure that the DoD is able to reduce its reliance on nations like China for its critical pharmaceutical needs.”
“The COVID-19 pandemic has demonstrated the vulnerability of our nation’s supply chains, including of pharmaceutical products,” Warren said. “This poses a risk not only to public health but to our national security. I’m glad to lead this bill with Senator Rubio to ensure DoD takes steps to reduce its reliance on pharmaceuticals manufactured abroad and to strengthen its supply chains,” said Senator Warren.
The Strengthening Supply Chains for Servicemembers and Security Act would codify the six recommendations included in the DoD OIG report to address supply chain weaknesses:
Recommendation that the Under Secretary of Defense for Acquisition and Sustainment:
- Develop and issue implementing guidance for DoD supply chain risk management for DoD material, which includes pharmaceuticals.
- Pursue Federal legislation requiring pharmaceutical manufacturers to include APIs and final drug product country of origin information of the pharmaceuticals’ lot on the pharmaceuticals’ packaging. Specifically, the legislation would require a further review of information gaps to address reliance concerns.
Recommendation that the Director of the Defense Health Agency:
- Develop and publish implementing guidance for supply chain risk management specifically for pharmaceuticals.
- Create a chartered work group to assess risks to the pharmaceutical supply chain, identify the pharmaceuticals most critical to beneficiary care at DoD MTFs, and establish policy for allocating scarce pharmaceutical resources in case of a supply disruption.
Recommendation that the Director of the Defense Logistics Agency modify DLA Instructions 5025.03 and 3110.01 to:
- Require DLA Troop Support to coordinate annually with Military Service customers to conduct responsiveness testing of the DLA’s contingency contracts for pharmaceuticals.
- Include the contract responsiveness testing results, as reported by the Military Service customers, in the Warstopper Program annual reports.